Compare Regeneron Pharmaceuticals Inc (REGN) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wells Fargo & Co — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Wells Fargo & Co trades at $89.84 (market cap $265.99B). The key difference: Wells Fargo & Co is far larger — about 3.2× Regeneron Pharmaceuticals Inc's market cap, and Wells Fargo & Co pays the higher dividend (2.27%). Which is the better fit depends on your goals.
| REGN | WFC | |
|---|---|---|
Market Cap | $83.43B | $265.99B |
Sector | Health | Financials |
52-Week High | $852.03 | $96.40 |
52-Week Low | $555.51 | $73.42 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Wells Fargo (WFC) trades at $87.98, down 2.21% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 12.78, net income margin of 25.97%, and recent Q2 2026 earnings beat. CEO Charlie Scharf emphasized strategic initiatives at the 2026 healthcare conference (CNBC, 2026-09-09), while the bank expands its wealth management division (Bloomberg via Yahoo Finance, 2026-08-28).
Outlook is cautiously positive with a consensus price target of $97.64, though risks include volatile cash flows and regulatory scrutiny. Investment opportunity lies in sustained profitability improvements and ROTCE targets, but investors face headwinds from interest rate sensitivity and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
